Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AVR vs DXR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DXR Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–3 Matrix Metrics)

DXR Overall Winner 6-Pillar Tally: AVR 2 – 3 DXR (1 Tie) Matrix Metrics: AVR 3 – 7 DXR

As of Nov 16, 2026, Daxor Corporation (DXR) is the stronger overall head-to-head candidate over Anteris Technologies Global Corp. (AVR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AVR carries a Unified Composite Score of 48.2/100 (HOLD) at $5.70 (N/M Forward P/E, -4880.4% operating margin), whereas DXR carries 52.2/100 (HOLD) at $8.36 (64.5x Forward P/E, -5894.3% operating margin).

  • Technical & Structure Timing Caution: AVR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.5); meanwhile DXR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVR vs DXR
AVR NASDAQ
Anteris Technologies Global Corp. Common Stock
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$5.70
+5.17% 1D
Market Cap $528.4M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol 1.56β · 77% Vol
Unified Composite Score
48.2 / 100 HOLD
Tech 58.0 Fund 49.0 Flow 57.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.2%), weak momentum, RSI 42
RSI-14: 42.5 · SMA20: $5.93 · SMA50: $6.90
DXR NASDAQ Head-to-Head Winner
Daxor Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$8.36
-1.47% 1D
Market Cap $49.5M
TTM Revenue $31,360
Forward P/E 64.5x
Beta / 30D Vol 0.28β · 32% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 52.0 Fund 59.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.2%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $8.91 · SMA50: $10.07

6-Pillar Scorecard Institutional Category Breakdown (AVR 2 – 3 DXR)

Columns: Metric · AVR · DXR
1. Valuation Multiples DXR
Forward P/E N/M 64.5x
Trailing P/E N/M 7.7x
PEG Ratio N/M N/M
EV / Revenue 133.9x N/M
2. Growth & Scale DXR
Revenue Growth (YoY) +21.0% +25.5%
Earnings Growth (YoY) +0.0% +329.3%
TTM Revenue (USD) $2.3M $31,360
Market Cap $528.4M $49.5M
3. Profitability & Quality DXR
Gross Margin 75.8% 100.0%
Operating Margin -4880.4% -5894.3%
Net Profit Margin 0.0% 19861.4%
Return on Equity (ROE) -93.3% 14.2%
4. Balance Sheet & Cash Flow AVR
Cash Generation (TTM) -$94M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $216M Net Cash $8.88 Book/Sh · 14.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AVR
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 58.5% (52nd %ile) N/A (N/A)
Put/Call OI Skew 0.66x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVR (3) vs DXR (7)
Institutional Metric AVR DXR Criterion Row Edge
Market Capitalization
Scale
$528.4M $49.5M Larger Scale AVR
Trailing P/E Ratio
Valuation
N/M 7.7x Lower Multiple DXR
Forward P/E Ratio
Valuation
N/M 64.5x Lower Multiple DXR
Revenue Growth (YoY)
Growth
+21.0% +25.5% Higher Growth DXR
Operating Margin (TTM)
Profitability
-4880.4% -5894.3% Higher Margin AVR
Net Profit Margin
Profitability
0.0% 19861.4% Higher Margin DXR
Return on Equity (ROE)
Capital Efficiency
-93.3% 14.2% Higher ROE DXR
52-Week Range Position
Momentum
31% ($3–$11) 2% ($8–$15) Stronger Trend AVR
Beta / 30D Volatility
Risk Regime
1.56β · 77% Vol 0.28β · 32% Vol Lower Realized Risk DXR
Unified Institutional Score
Composite Signal
48.2 / 100 (HOLD) 52.2 / 100 (HOLD) Higher Composite DXR
Trailing 12M Revenue (USD)
Operating Scale
$2.3M $31,360 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.8% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 133.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$94M ($216M Net Cash) N/A ($8.88 Book/Sh · 14.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AVR +11.08 pp
AVR: -5.79% · DXR: -16.87%
3M Horizon DXR +16.51 pp
AVR: -36.17% · DXR: -19.66%
6M Horizon AVR +10.43 pp
AVR: -7.01% · DXR: -17.44%
1Y Horizon AVR +83.67 pp
AVR: +50.4% · DXR: -33.27%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVR vs DXR. Trailing 12-month operating profitability (AVR -4880.4% vs DXR -5894.3%) and valuation multiples (AVR N/M vs DXR 64.5x Forward P/E) are benchmarked directly in Pillar 4 below.

AVR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.3M
Gross Margin75.8%
Op. Margin-4880.4%
ROE / Fwd P/E-93.3% · N/M
DXR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$31,360
Gross Margin100.0%
Op. Margin-5894.3%
ROE / Fwd P/E14.2% · 64.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVR BREAKDOWN
101d in phase · OBV NEUTRAL
Current IV 58.5%
IV Percentile 52nd %ile
Put/Call OI Skew 0.66x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact AVR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DXR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DXR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVR Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $528.4M market capitalization and -4880.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DXR Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $49.5M market capitalization and -5894.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AVR vs DXR Key Questions & Quantitative Answers

As of Nov 16, 2026, Daxor Corporation (DXR) is the stronger overall head-to-head candidate over Anteris Technologies Global Corp. (AVR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AVR carries a Unified Composite Score of 48.2/100 (HOLD) at $5.70 (N/M Forward P/E, -4880.4% operating margin), whereas DXR carries 52.2/100 (HOLD) at $8.36 (64.5x Forward P/E, -5894.3% operating margin). Technical & Structure Timing Caution: AVR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.5); meanwhile DXR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DXR leads the Growth & Scale pillar: AVR posts +21.0% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (75.8% gross margin, -4880.4% operating margin), compared with DXR at +25.5% YoY revenue growth and +329.3% YoY earnings growth on $31,360 TTM revenue (100.0% gross margin, -5894.3% operating margin). On trailing 12-month operating scale, AVR generates $2.3M in USD-normalized revenue versus $31,360 for DXR. In operating R&D and SG&A reinvestment, AVR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DXR.

DXR screens cheaper on headline valuation multiples. AVR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 133.9x EV/Revenue (unreported FCF margin), whereas DXR trades at 64.5x Forward P/E, 7.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVR (-93.3% ROE) versus DXR (14.2% ROE) capital efficiency.

In options market volatility and institutional positioning, AVR carries 58.5% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.66x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.56β · 77% Vol realized risk). By comparison, DXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.28β · 32% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.